Implementing Germline and Somatic Testing for Precision Medicine in Community-Based Prostate Cancer Care Visiting Professorship Program
Supports US community urology/oncology practices to host expert-led educational programs on integrating germline and somatic testing into prostate cancer care.
Funder: Pfizer Inc.
Due Dates: June 23, 2026 (Full application due by 23:59 ET)
Funding Amounts: Up to $50,000 per award; total RFP budget $250,000; 5–7 awards expected; project period Nov 1, 2026–May 1, 2027
Summary: Supports US community-based urology or oncology practices to host expert-led educational programs on integrating germline and somatic testing for prostate cancer care.
Key Information: Only community-based US organizations are eligible; Visiting Professor costs are funded separately from the grant.
Description
This grant opportunity is designed to support community-based urology and oncology organizations in the United States to host a 2.5–3 hour medical education program led by expert Visiting Professors. The focus is on implementing or improving germline and somatic (tumor and/or ctDNA) testing for prostate cancer patients. The program aims to address knowledge gaps, improve provider education, and foster sustainable practice-level solutions in precision medicine, ultimately enhancing patient outcomes.
